The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Targeting KRAS: future directions
Giuseppe Lamberti, MD, University Hospital of Bologna, Bologna, Italy, discusses developments in KRAS as a druggable target. Currently, only KRAS inhibitors targeting the KRASG12C mutation have been approved, however pan-KRAS inhibitors are currently in development. Additionally, KRAS inhibitors that cross the blood-brain barriers (BBB) are under investigation to increase intracranial activity. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
![Impact of [18F]FDG PET/CT-derived metabolic parameters on outcomes in extensive-stage SCLC](https://i.ytimg.com/vi/soBIdqv8jvQ/mqdefault.jpg)
